News
Public · Published
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome
Rhythm Pharmaceuticals said NICE issued positive guidance expanding NHS-funded access to IMCIVREE (setmelanotide) for adults with genetically confirmed Bardet-Biedl syndrome. The updated guidance builds on NICE's May 2024 recommendation, which covered treatment initiation for patients aged 6 to 17, and considered additional clinical, real-world and longer-term evidence.
Published:
Updated:
What happened
Rhythm Pharmaceuticals said NICE issued positive guidance expanding NHS-funded access to IMCIVREE (setmelanotide) for adults with genetically confirmed Bardet-Biedl syndrome. The updated guidance builds on NICE’s May 2024 recommendation, which covered treatment initiation for patients aged 6 to 17, and considered additional clinical, real-world and longer-term evidence.
Confirmed
Global impact / market context
The guidance makes NHS-funded treatment available to a broader group, potentially increasing eligible patients and demand for IMCIVREE. If treatment uptake grows, Rhythm could gain revenue, while the size of any benefit depends on eligible patient numbers, prescribing and NHS access in the covered regions.
Analyst inference
This is a reimbursement expansion rather than a reported change to the medicine or a new clinical trial result. NICE’s assessment drew on additional evidence and recognized the condition’s effects on patients and families; the article gives no sales, uptake or financial forecast.
Confirmed
What to watch
- Watch for Rhythm to report how many adults become eligible and whether NHS-funded treatment begins across England, Wales and Northern Ireland, the regions identified in the article. Analyst inference
- Future company updates could clarify prescribing rates and revenue contribution from adult patients; these would show whether expanded eligibility translates into actual treatment demand. Analyst inference
- The article says NICE considered additional clinical, real-world and longer-term evidence, but provides no details on the size or results of those data sets. Confirmed